-
While emerging multidrug resistant gram negative rods are a prime topic of current concern, there is a sobering reminder that longstanding foes have not exactly been vanquished.
-
As a key complement to its new antibiotic use tracking system, the Centers for Disease Control and Prevention is partnering with the Institute for Healthcare Improvement (IHI) in a pilot program to prevent overuse and misuse of antibiotics in hospitals.
-
This report details the occurrence of an infected, cellulitic lower extremity wound infection in a 70-year-old British woman secondary to an unusual Vibrio species, V. alginolyticus.
-
Outpatients with a diagnosis of either dentoalveolar or periodontal abscess or a diagnosis of gingival inflammatory infiltrates were randomized to receive either moxifloxacin 400 mg daily or clindamycin 300 mg QID, both for 5 days, in a prospective, randomized, placebo-controlled, double-dummy clinical trial design.
-
Rivaroxaban (Xarelto), Janssen Pharmaceutical's once-a-day oral Xa inhibitor, has been approved for reducing the risk of stroke in patients with atrial fibrillation.
-
-
An updated meta-analysis of birth defects in infants with first trimester efavirenz exposure was conducted and included published literature up until July 2011.
-
The toxicity associated with intestinal habitation by Clostridium difficile ranges from asymptomatic colonization to life-threatening infection. In the United States, C. difficile is the most common cause of health care-associated diarrhea.
-
A low-dose sublingual formulation of Zolpidem has been approved by the FDA for the management of middle-of-the-night (MOTN) awakening. Zolpidem, marketed as Ambien, was originally approved in 1992. The new formulation is marketed by Transcept Pharmaceuticals as Intermezzo.
-
The use of ambulatory blood pressure (BP)monitoring as a diagnostic strategy for the diagnosis of hypertension after finding an initial raised BP reading in the doctor's office would reduce misdiagnosis. The additional costs of ambulatory monitoring are counterbalanced by cost savings from better targeted therapy and, therefore, ambulatory monitoring is recommended for most patients before the start of antihypertensive drug therapy.